BC Week In Review | Apr 15, 2013
Clinical News

Sustiva data

DuPont Merck presented data at the Infectious Diseases Society of America meeting in San Francisco from an ongoing Phase II study comparing the combination of Sustiva and Merck's Crixivan indinavir HIV protease inhibitor against indinavir...
BioCentury | Aug 13, 2012

Merck's new mark in HIV

Merck & Co. Inc. may be positioning itself to compete in the HIV combination therapy market dominated by Gilead Sciences Inc. and ViiV Healthcare LLC , the joint venture of GlaxoSmithKline plc and Pfizer Inc. Merck...
BC Week In Review | Apr 4, 2011
Company News

Gilead, Abbott, Boehringer Ingelheim, Bristol-Myers, GlaxoSmithKline, J&J, Merck, Pfizer, Roche infectious news

California State Controller John Chiang sent letters to eight companies requesting they extend and expand existing supplemental price reduction and rebate program for its HIV/AIDS drugs with California's AIDS Drug Assistance Program (ADAP). The Controller...
BC Week In Review | Jul 19, 2010
Company News

Abbott, Merck, Heinz Family Philanthropies, Welvista infectious news

Merck joined an existing collaboration with Abbott, the Heinz Family and not-for-profit Welvista to provide free HIV/AIDS medications to patients on waiting lists for the AIDS Drug Assistance Program (ADAP). Abbott will provide its Norvir...
BC Innovations | Jun 12, 2008
Targets & Mechanisms

Eyeing New Uses for Protease Inhibitors

A paper in the Journal of Clinical Investigation indicates that HIV protease inhibitors could be repurposed as neuroprotectants to block apoptosis in age-related macular degeneration, diabetic retinopathy and other conditions involving neuronal apoptosis. 1 The...
BC Week In Review | Jun 25, 2007
Clinical News

Crixivan indinavir sulphate regulatory update

CHMP issued a recommendation to add a contraindication for the concomitant use of Crixivan indinavir with midazolam given orally. The HIV protease inhibitor is approved to treat HIV infection in combination with antiretroviral agents. Merck...
BioCentury | Feb 9, 2004

Incyte: The long goodbye

In December 2001, Incyte Corp. began making the transition from a genomics database company to a company focused on therapeutic development. Last week, INCY finally announced that it is closing the Palo Alto, Calif., facility...
BC Week In Review | Mar 4, 2002
Company News

Istituto Superiore di Sanita other research news

Researchers published in Nature Medicine evidence that the HIV protease inhibitors Crixivan indinavir from Merck & Co. Inc. (MRK, Whitehouse Station, N.J.) and Invirase saquinavir from F. Hoffmann-La Roche Ltd. (SWX:ROCZ, Basel, Switzerland) inhibit angiogenesis...
BC Week In Review | Oct 22, 2001
Company News

Merck other research news

Researchers from the University of Cincinnati published in the Proceedings of the National Academy of Sciences the mechanism of indirect hyperbilirubinemia that occurs in up to 25% of HIV patients treated with indinavir. They showed...
BioCentury | Oct 22, 2001
Tools & Techniques

Elucidating Crixivan side effect

The HIV protease inhibitor Crixivan indinavir causes signs of potential liver side effects in up to 25% of patients taking the product, causing physicians to change treatment. Researchers now have identified the mechanism responsible for...
Items per page:
1 - 10 of 82